Title : Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.

Pub. Date : 2022 Apr 4

PMID : 35373356






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lorlatinib is a third-generation, brain-penetrant ALK and ROS1 tyrosine kinase inhibitor (TKI) with robust intracranial activity in patients with ALK- or ROS1-positive non-small cell lung cancer (NSCLC). lorlatinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens
2 Lorlatinib is a third-generation, brain-penetrant ALK and ROS1 tyrosine kinase inhibitor (TKI) with robust intracranial activity in patients with ALK- or ROS1-positive non-small cell lung cancer (NSCLC). lorlatinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens